- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00217984
Intensive Intervention for Smokers - 6
Intensive Intervention for Smokers in Alcohol Treatment
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Introduction. The purpose of this study was to investigate the efficacy of an intensive tobacco cessation intervention for alcohol-dependent smokers in early recovery.
Methods. A total of 162 alcohol-dependent smokers were randomized to either intensive intervention for smoking cessation or usual care. The intensive intervention consisted of 16 sessions of individual cognitive behavior therapy (CBT) and combination nicotine replacement therapy that lasted 26 weeks. Usual care involved referral to a free-standing smoking cessation program that provided smoking cessation counseling of varying duration and guideline-concordant medications. The primary cessation outcome was verified 7-day point prevalence abstinence (PPA) at 12, 26, 38, and 52 weeks.
Results. At 12 and 26 weeks, the verified 7-day point-prevalence quit rate was significantly higher for the intensive intervention group than for the usual care group (both p = .03). However, the quit rates for the two treatment groups were not significantly different at 38 or 52 weeks. Verified 30-day alcohol abstinence rates were not significantly different for the two treatment groups at any of the follow-up assessments.
Conclusions. The intensive smoking cessation intervention yielded a higher short-term smoking quit rate without jeopardizing sobriety. A chronic care model might facilitate maintenance of smoking cessation during the first year of alcohol treatment and perhaps for longer periods of time. It is hoped that studies such as this will inform the development of more effective interventions for concurrent alcohol and tobacco use disorders.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
California
-
San Francisco, California, Verenigde Staten, 94121
- VA Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- at least 18 years of age
- alcohol as primary drug of abuse
- currently smoking at least 10 or more cigarettes
- abstinent from alcohol for at least 7 days and not more than 30 days
- self-reported interest in quitting smoking
Exclusion Criteria:
- any contraindications for nicotine patches or lozenges (e.g., unstable angina or recent myocardial infarction
- skin allergy to the nicotine patch
- severe cardiovascular disease
- lactation
- pregnancy by self-report or by positive serum pregnancy test in pre-menopausal women)
- unstable psychiatric disorder
- severe cognitive impairment
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Intensive intervention
Extended cognitive behavior therapy (16 sessions) plus nicotine patches and lozenges
|
16 sessions of cognitive behavior therapy over 6 months
|
|
Ander: Usual care
Referral to the smoking cessation clinic
|
Referral to smoking cessation clinic
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
7 day point prevalence of cigarette abstinence
Tijdsspanne: Assessed at 3, 6, 9, and 12 months
|
Participants are asked whether they smoked any cigarettes during the past seven days.
Expired-air carbon monoxide is measured to validate abstinence.
|
Assessed at 3, 6, 9, and 12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Alcohol use
Tijdsspanne: Assessed at 3, 6, 9, and 12 months
|
Participants were asked to report use of alcohol during the past 90 days, using a timeline follow-back interview method
|
Assessed at 3, 6, 9, and 12 months
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Timothy Carmody, Ph.D., University of California, San Francisco
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- NIDA-09253-6
- P50DA009253 (Subsidie/contract van de Amerikaanse NIH)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .